{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T19:23:56Z","timestamp":1767900236688,"version":"3.49.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Obstetrics and Gynecology Clinics of North America"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.ogc.2022.10.008","type":"journal-article","created":{"date-parts":[[2023,2,21]],"date-time":"2023-02-21T22:04:50Z","timestamp":1677017090000},"page":"39-78","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Antihypertensives in Pregnancy"],"prefix":"10.1016","volume":"50","author":[{"given":"Anna E.","family":"Denoble","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah A.","family":"Goldstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian M.","family":"Pettker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ogc.2022.10.008_bib1","doi-asserted-by":"crossref","first-page":"134 e131","DOI":"10.1016\/j.ajog.2011.10.878","article-title":"Prevalence, trends, and outcomes of chronic hypertension: a nationwide sample of delivery admissions","volume":"206","author":"Bateman","year":"2012","journal-title":"Am J Obstet Gynecol"},{"issue":"11","key":"10.1016\/j.ogc.2022.10.008_bib2","doi-asserted-by":"crossref","first-page":"e025050","DOI":"10.1161\/JAHA.121.025050","article-title":"Temporal trends in adverse pregnancy outcomes in birthing individuals aged 15 to 44 years in the United States, 2007 to 2019","volume":"11","author":"Freaney","year":"2022","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"19","key":"10.1016\/j.ogc.2022.10.008_bib3","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa2201295","article-title":"Treatment for mild chronic hypertension during pregnancy","volume":"386","author":"Tita","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"17","key":"10.1016\/j.ogc.2022.10.008_bib4","first-page":"e484","volume":"138","author":"Whelton","year":"2018","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.ogc.2022.10.008_bib5","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1097\/AOG.0000000000003020","article-title":"Chronic hypertension in pregnancy: ACOG Practice Bulletin Number 203","volume":"133","year":"2019","journal-title":"Obstet Gynecol"},{"issue":"6","key":"10.1016\/j.ogc.2022.10.008_bib6","doi-asserted-by":"crossref","first-page":"e237","DOI":"10.1097\/AOG.0000000000003891","article-title":"Gestational hypertension and preeclampsia: ACOG Practice Bulletin, Number 222","volume":"135","year":"2020","journal-title":"Obstet Gynecol"},{"issue":"2","key":"10.1016\/j.ogc.2022.10.008_bib7","doi-asserted-by":"crossref","first-page":"B24","DOI":"10.1016\/j.ajog.2022.04.011","article-title":"Electronic address pso. Society for Maternal-Fetal Medicine Statement: Antihypertensive therapy for mild chronic hypertension in pregnancy-The Chronic Hypertension and Pregnancy trial","volume":"227","author":"Society for Maternal-Fetal","year":"2022","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ogc.2022.10.008_bib8","author":"ACoOa"},{"issue":"3","key":"10.1016\/j.ogc.2022.10.008_bib9","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1161\/HYPERTENSIONAHA.121.18415","article-title":"Oral antihypertensives for nonsevere pregnancy hypertension: systematic review, network meta- and trial sequential analyses","volume":"79","author":"Bone","year":"2022","journal-title":"Hypertension"},{"issue":"2","key":"10.1016\/j.ogc.2022.10.008_bib10","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/bdrb.20238","article-title":"Antihypertensive medication use during pregnancy and the risk of major congenital malformations or small-for-gestational-age newborns","volume":"89","author":"Nakhai-Pour","year":"2010","journal-title":"Birth Defects Res B Dev Reprod Toxicol"},{"issue":"2","key":"10.1016\/j.ogc.2022.10.008_bib11","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1161\/HYPERTENSIONAHA.111.00833","article-title":"The risk of congenital malformations associated with exposure to beta-blockers early in pregnancy: a meta-analysis","volume":"62","author":"Yakoob","year":"2013","journal-title":"Hypertension"},{"issue":"4","key":"10.1016\/j.ogc.2022.10.008_bib12","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.ajog.2020.03.016","article-title":"Comparative efficacy and safety of oral antihypertensive agents in pregnant women with chronic hypertension: a network metaanalysis","volume":"223","author":"Bellos","year":"2020","journal-title":"Am J Obstet Gynecol"},{"issue":"11","key":"10.1016\/j.ogc.2022.10.008_bib13","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1111\/jch.13397","article-title":"Beta-blocker subtypes and risk of low birth weight in newborns","volume":"20","author":"Duan","year":"2018","journal-title":"J\u00a0Clin Hypertens (Greenwich)"},{"issue":"1","key":"10.1016\/j.ogc.2022.10.008_bib14","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ultrasmedbio.2010.10.006","article-title":"Changes in fetal and maternal Doppler parameters observed during acute severe hypertension treatment with hydralazine or labetalol: a randomized controlled trial","volume":"37","author":"Baggio","year":"2011","journal-title":"Ultrasound Med Biol"},{"key":"10.1016\/j.ogc.2022.10.008_bib15","first-page":"CD002252","article-title":"Antihypertensive drug therapy for mild to moderate hypertension during pregnancy","volume":"10","author":"Abalos","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.ogc.2022.10.008_bib16","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1161\/HYPERTENSIONAHA.119.13802","article-title":"In utero antihypertensive medication exposure and neonatal outcomes: a data linkage cohort study","volume":"75","author":"Fitton","year":"2020","journal-title":"Hypertension"},{"issue":"12","key":"10.1016\/j.ogc.2022.10.008_bib17","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S1701-2163(16)30592-8","article-title":"Fall in mean arterial pressure and fetal growth restriction in pregnancy hypertension: an updated metaregression analysis","volume":"24","author":"von Dadelszen","year":"2002","journal-title":"J\u00a0Obstet Gynaecol Can"},{"issue":"4","key":"10.1016\/j.ogc.2022.10.008_bib18","doi-asserted-by":"crossref","first-page":"301 e301","DOI":"10.1016\/j.ajog.2012.11.011","article-title":"Hypertension and antihypertensive drugs in pregnancy and perinatal outcomes","volume":"208","author":"Orbach","year":"2013","journal-title":"Am J Obstet Gynecol"},{"issue":"2","key":"10.1016\/j.ogc.2022.10.008_bib19","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/pds.2068","article-title":"Risks of congenital malformations and perinatal events among infants exposed to calcium channel and beta-blockers during pregnancy","volume":"20","author":"Davis","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"10.1016\/j.ogc.2022.10.008_bib20","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.reprotox.2008.05.065","article-title":"The safety of calcium channel blockers during pregnancy: a prospective, multicenter, observational study","volume":"26","author":"Weber-Schoendorfer","year":"2008","journal-title":"Reprod Toxicol"},{"issue":"5","key":"10.1016\/j.ogc.2022.10.008_bib21","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1034\/j.1600-0412.2001.080005397.x","article-title":"The risk of limb deficiencies and other congenital abnormalities in children exposed in utero to calcium channel blockers","volume":"80","author":"Sorensen","year":"2001","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"2\u20133","key":"10.1016\/j.ogc.2022.10.008_bib22","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2535\/ofaj1936.52.2-3_103","article-title":"Effects of diltiazem hydrochloride on embryonic development: species differences in the susceptibility and stage specificity in mice, rats, and rabbits","volume":"52","author":"Ariyuki","year":"1975","journal-title":"Okajimas Folia Anat Jpn"},{"issue":"2","key":"10.1016\/j.ogc.2022.10.008_bib23","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/AOG.0000000000000908","article-title":"Calcium channel blocker exposure in late pregnancy and the risk of neonatal seizures","volume":"126","author":"Bateman","year":"2015","journal-title":"Obstet Gynecol"},{"issue":"6 Pt 1","key":"10.1016\/j.ogc.2022.10.008_bib24","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1016\/0002-9378(90)90762-V","article-title":"The effect of nifedipine therapy on fetal and placental Doppler waveforms in preeclampsia remote from term","volume":"163","author":"Moretti","year":"1990","journal-title":"Am J Obstet Gynecol"},{"issue":"8273","key":"10.1016\/j.ogc.2022.10.008_bib25","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/S0140-6736(82)92202-4","article-title":"Final report of study on hypertension during pregnancy: the effects of specific treatment on the growth and development of the children","volume":"1","author":"Cockburn","year":"1982","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ogc.2022.10.008_bib26","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1161\/HYPERTENSIONAHA.117.09110","article-title":"Pregnancy outcome after first trimester use of methyldopa: a prospective cohort study","volume":"70","author":"Hoeltzenbein","year":"2017","journal-title":"Hypertension"},{"issue":"7","key":"10.1016\/j.ogc.2022.10.008_bib27","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1161\/HYPERTENSIONAHA.122.18920","article-title":"Role of antihypertensive treatment and blood pressure control in the occurrence of adverse pregnancy outcomes: a population-based study of linked electronic health records","volume":"79","author":"Al Khalaf","year":"2022","journal-title":"Hypertension"},{"key":"10.1016\/j.ogc.2022.10.008_bib28","doi-asserted-by":"crossref","first-page":"110196","DOI":"10.1016\/j.biopha.2020.110196","article-title":"Methyldopa as an inductor of postpartum depression and maternal blues: a review","volume":"127","author":"Wicinski","year":"2020","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"10.1016\/j.ogc.2022.10.008_bib29","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1080\/01443615.1986.11978611","article-title":"Transfer of hydralazine across the placenta and into breast milk","volume":"7","author":"Lamont","year":"1986","journal-title":"J\u00a0Obstet Gynaecol"},{"issue":"3","key":"10.1016\/j.ogc.2022.10.008_bib30","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1055\/s-2007-999491","article-title":"Severe preeclampsia: is vasodilation therapy with hydralazine dangerous for the preterm fetus?","volume":"7","author":"Derham","year":"1990","journal-title":"Am J Perinatol"},{"key":"10.1016\/j.ogc.2022.10.008_bib31","first-page":"CD001449","article-title":"Drugs for treatment of very high blood pressure during pregnancy","volume":"7","author":"Duley","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ogc.2022.10.008_bib32","doi-asserted-by":"crossref","first-page":"0267","DOI":"10.1136\/bmj.290.6461.17","article-title":"Overview of randomised trials of diuretics in pregnancy","volume":"290","author":"Collins","year":"1985","journal-title":"Br Med J"},{"issue":"2","key":"10.1016\/j.ogc.2022.10.008_bib33","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1006\/faat.1995.1088","article-title":"The evaluation of the developmental toxicity of hydrochlorothiazide in mice and rats","volume":"26","author":"George","year":"1995","journal-title":"Fundam Appl Toxicol"},{"issue":"7","key":"10.1016\/j.ogc.2022.10.008_bib34","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/0002-9378(84)90458-7","article-title":"Effects of diuretics on plasma volume in pregnancies with long-term hypertension","volume":"150","author":"Sibai","year":"1984","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ogc.2022.10.008_bib35","first-page":"CD004451","article-title":"Diuretics for preventing pre-eclampsia","volume":"1","author":"Churchill","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.ogc.2022.10.008_bib36","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1159\/000299817","article-title":"Placental transfer of hydrochlorothiazide","volume":"11","author":"Beermann","year":"1980","journal-title":"Gynecol Obstet Invest"},{"issue":"1","key":"10.1016\/j.ogc.2022.10.008_bib37","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/0041-008X(81)90144-7","article-title":"Potassium loss as a causative factor for skeletal malformations in rats produced by indacrinone: a new investigational loop diuretic","volume":"60","author":"Robertson","year":"1981","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.ogc.2022.10.008_bib38","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.earlhumdev.2018.08.009","article-title":"Prolonged furosemide exposure and risk of abnormal newborn hearing screen in premature infants","volume":"125","author":"Wang","year":"2018","journal-title":"Early Hum Dev"},{"issue":"23","key":"10.1016\/j.ogc.2022.10.008_bib39","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa055202","article-title":"Major congenital malformations after first-trimester exposure to ACE inhibitors","volume":"354","author":"Cooper","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.ogc.2022.10.008_bib40","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ijcard.2014.09.013","article-title":"Cardiac medication during pregnancy, data from the ROPAC","volume":"177","author":"Ruys","year":"2014","journal-title":"Int J Cardiol"},{"issue":"1","key":"10.1016\/j.ogc.2022.10.008_bib41","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/AOG.0000000000001775","article-title":"Angiotensin-converting enzyme inhibitors and the risk of congenital malformations","volume":"129","author":"Bateman","year":"2017","journal-title":"Obstet Gynecol"},{"issue":"2","key":"10.1016\/j.ogc.2022.10.008_bib42","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1161\/HYPERTENSIONAHA.112.196352","article-title":"Pregnancy outcome following exposure to angiotensin-converting enzyme inhibitors or angiotensin receptor antagonists: a systematic review","volume":"60","author":"Bullo","year":"2012","journal-title":"Hypertension"},{"issue":"6","key":"10.1016\/j.ogc.2022.10.008_bib43","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1007\/s00404-022-06504-5","article-title":"Nifedipine or amlodipine? The choice for hypertension during pregnancy: a systematic review and meta-analysis","volume":"306","author":"Yin","year":"2022","journal-title":"Arch Gynecol Obstet"},{"issue":"9","key":"10.1016\/j.ogc.2022.10.008_bib44","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1111\/bcp.13649","article-title":"Drugs for treating severe hypertension in pregnancy: a network meta-analysis and trial sequential analysis of randomized clinical trials","volume":"84","author":"Sridharan","year":"2018","journal-title":"Br J Clin Pharmacol"},{"issue":"7421","key":"10.1016\/j.ogc.2022.10.008_bib45","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1136\/bmj.327.7421.955","article-title":"Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis","volume":"327","author":"Magee","year":"2003","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.ogc.2022.10.008_bib46","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/1471-0528.13463","article-title":"Oral nifedipine versus intravenous labetalol for severe hypertension during pregnancy: a systematic review and meta-analysis","volume":"123","author":"Shekhar","year":"2016","journal-title":"BJOG"},{"issue":"5","key":"10.1016\/j.ogc.2022.10.008_bib47","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1097\/AOG.0b013e3182a9ea68","article-title":"Oral nifedipine or intravenous labetalol for hypertensive emergency in pregnancy: a randomized controlled trial","volume":"122","author":"Shekhar","year":"2013","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ogc.2022.10.008_bib48","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.preghy.2019.09.019","article-title":"First-line antihypertensive treatment for severe hypertension in pregnancy: a systematic review and network meta-analysis","volume":"18","author":"Alavifard","year":"2019","journal-title":"Pregnancy Hypertens"},{"issue":"1","key":"10.1016\/j.ogc.2022.10.008_bib49","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1161\/HYPERTENSIONAHA.117.09799","article-title":"Prevalence of hypertensive phenotypes after preeclampsia: a prospective cohort study","volume":"71","author":"Ditisheim","year":"2018","journal-title":"Hypertension"},{"issue":"3","key":"10.1016\/j.ogc.2022.10.008_bib50","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1161\/HYPERTENSIONAHA.117.10338","article-title":"Blood pressure profile 1 year after severe preeclampsia","volume":"71","author":"Benschop","year":"2018","journal-title":"Hypertension"},{"issue":"11","key":"10.1016\/j.ogc.2022.10.008_bib51","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1038\/s41569-020-0390-z","article-title":"Pregnancy and cardiovascular disease","volume":"17","author":"Ramlakhan","year":"2020","journal-title":"Nat Rev Cardiol"},{"issue":"11","key":"10.1016\/j.ogc.2022.10.008_bib52","doi-asserted-by":"crossref","first-page":"e018696","DOI":"10.1136\/bmjopen-2017-018696","article-title":"Postpartum management of hypertensive disorders of pregnancy: a systematic review","volume":"7","author":"Cairns","year":"2017","journal-title":"BMJ Open"},{"issue":"8","key":"10.1016\/j.ogc.2022.10.008_bib53","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1080\/14656566.2019.1594773","article-title":"Pharmacotherapy for hypertension in pregnant patients: special considerations","volume":"20","author":"Tamargo","year":"2019","journal-title":"Expert Opin Pharmacother"},{"issue":"3","key":"10.1016\/j.ogc.2022.10.008_bib54","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s11095-018-2352-2","article-title":"Pregnancy-associated changes in pharmacokinetics and their clinical implications","volume":"35","author":"Koren","year":"2018","journal-title":"Pharm Res"}],"container-title":["Obstetrics and Gynecology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889854522000997?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889854522000997?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:26:33Z","timestamp":1760178393000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889854522000997"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S0889854522000997"],"URL":"https:\/\/doi.org\/10.1016\/j.ogc.2022.10.008","relation":{},"ISSN":["0889-8545"],"issn-type":[{"value":"0889-8545","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antihypertensives in Pregnancy","name":"articletitle","label":"Article Title"},{"value":"Obstetrics and Gynecology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ogc.2022.10.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}